Can You Take GLP-1 Medications After ESG? Semaglutide & Tirzepatide Explained
Can You Take GLP-1 Medications After ESG?
Patients often ask whether Endoscopic Sleeve Gastroplasty means they will never need weight-loss medication again—or whether medications such as Wegovy®, Ozempic®, Zepbound®, or Mounjaro® should automatically be added after ESG.
The answer is more individualized. ESG and GLP-1-based medications address different parts of weight management. ESG changes functional stomach volume and supports smaller portions, while medications such as semaglutide and tirzepatide influence biological pathways involved in hunger and satiety.
Some patients progress well after ESG without medication. Others may later benefit from medical therapy because of persistent hunger, a prolonged plateau, less-than-expected weight loss, or weight regain. The goal is not to use the most treatments—it is to determine which treatment is appropriate at each stage.
Why Would Someone Need Medication After ESG?
ESG Works on Anatomy. Medication Works on Biology.
During Endoscopic Sleeve Gastroplasty (ESG), internal sutures reshape the stomach without abdominal incisions or surgical removal of stomach tissue. The goal is to help patients feel satisfied with smaller portions.
Weight-loss medications work through a different mechanism. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors.
This is why the treatments may sometimes complement each other: one changes stomach capacity, while the other can influence hunger and fullness.
ESG
Procedure-based treatment that reduces functional stomach volume and supports smaller meals without removing stomach tissue.
GLP-1 / GIP-GLP-1 Medication
Prescription treatment that influences appetite, satiety, food intake, and related metabolic pathways while therapy continues.
5 Reasons Medication May Be Discussed After ESG
1. Less Weight Loss Than Expected
If progress remains below the individualized treatment goal despite appropriate follow-up, the plan may need reassessment.
2. Persistent Hunger
Some patients still experience substantial appetite even when smaller meals are physically easier after ESG.
3. A Prolonged Plateau
A short plateau is common. A longer stall may lead the care team to review nutrition, activity, anatomy, and medication options.
4. Weight Regain
When weight returns later, the cause should be evaluated before choosing medication, endoscopic revision, or another approach.
5. Previous Medication Response
A patient who previously responded well to a GLP-1 medication may be considered for future medical therapy if clinically appropriate.
Should Wegovy® or Zepbound® Start Immediately After ESG?
Not Automatically
Starting medication immediately after ESG may make sense for some patients, but it should not be treated as a routine requirement. If ESG alone is producing steady progress, adding another treatment may increase cost, side effects, and treatment burden without a clear need.
For another patient with significant appetite, metabolic disease, or a history of inadequate response to procedure-only treatment, combination therapy may be considered earlier.
The broader evidence is discussed in our article ESG vs Ozempic: Own Your Weight Loss or Rent It?.
Why the Early Post-ESG Period Needs Extra Care
ESG and GLP-1 Medications Can Both Affect the GI Tract
After ESG, temporary nausea, abdominal pressure, reflux, or changes in food tolerance can occur during recovery. GLP-1-based medications can also cause gastrointestinal side effects such as nausea, vomiting, constipation, diarrhea, or abdominal discomfort.
That is why medication timing matters. The care team needs to distinguish expected post-procedure recovery symptoms from medication-related effects.
See our ESG recovery and weight-loss timeline and what actually happens after ESG.
Does ESG Plus Medication Always Work Better?
The Evidence Is More Nuanced Than “More Is Better”
A 2026 systematic review comparing ESG alone with ESG plus anti-obesity medication found a modest early average weight-loss advantage for combination treatment, but the difference was not statistically significant and consistent long-term superiority was not established.
You can also compare the leading medication approaches in Ozempic® vs Zepbound® for weight loss.
Can Medication Help if Weight Returns After ESG?
Possibly—but First Find Out Why the Weight Returned
Weight regain can involve appetite, metabolic adaptation, eating patterns, medications, sleep, physical activity, or anatomical changes. A prescription alone may not address the real cause.
If anatomy remains effective but hunger has increased, medication may be reasonable. If anatomy has changed, another endoscopic strategy may be more appropriate. If nutrition or another medical factor is driving regain, that may need to be addressed first.
Read more about weight regain after bariatric procedures.
You Do Not Have to Choose Only One Treatment Forever
Obesity Treatment Can Change Over Time
A patient’s treatment path may look like:
Medication → ESG → no medication
ESG → plateau → medication
Medication → inadequate durability → ESG
ESG + medication for selected patients.
The sequence should follow the patient’s health, goals, response, and tolerance—not a predetermined formula.
Learn More About ESG and Weight-Loss Medications
Considering GLP-1 Medication Before or After ESG?
At EndoSlim Clinic NY in Brooklyn, Dr. Alexander Shapsis can review your BMI, medical history, prior treatment, hunger patterns, medication tolerance, weight-loss progress, and goals to determine whether ESG, medication, or a combination strategy may be appropriate.
Serving: Brooklyn, Manhattan, Queens, the Bronx, Staten Island, Long Island, New Jersey, and Connecticut.
-
Mon-Friday: 08:30 - 6:00Saturday: ClosedSaturday: Closed